Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
Entered into global partnership with CSL to develop and commercialize self-amplifying mRNA vaccines targeting COVID-19, influenza, additional pathogens, and pandemic preparedness with $200 million upfront and up to $4.3 billion in potential development and commercial milestones BARDA award announced for up to $63.2 million to support development of a self-amplifying mRNA vaccine for rapid pandemic … [Read more…]
